Administration of Atezolizumab and Bevacizumab for Hepatocellular Carcinoma
Administer atezolizumab 1200 mg intravenously followed by bevacizumab 15 mg/kg intravenously every 3 weeks (21-day cycles) until disease progression or unacceptable toxicity, with atezolizumab given first when both drugs are administered on the same day 1.
Dosing Regimen
The standard FDA-approved dosing schedule for HCC is 1:
- Atezolizumab: 1200 mg IV every 3 weeks (alternative schedules: 840 mg every 2 weeks or 1680 mg every 4 weeks are also approved)
- Bevacizumab: 15 mg/kg IV every 3 weeks
- Sequence: Always administer atezolizumab prior to bevacizumab when given on the same day
- Duration: Continue until disease progression or unacceptable toxicity
Infusion Administration
First infusion 1:
- Atezolizumab: 60-minute IV infusion
- Bevacizumab: Follow after atezolizumab completion
Subsequent infusions 1:
- If first infusion tolerated: May reduce to 30-minute infusions
- Inspect vials visually for particulate matter/discoloration before use
- Do not shake vials
Pre-Treatment Assessments
Before initiating therapy, perform these mandatory evaluations 2:
Variceal screening and management:
- Upper GI endoscopy within 6 months for patients with portal hypertension
- Adequately treat any varices before starting bevacizumab
- This is critical as bevacizumab increases bleeding risk
- Child-Pugh class A liver disease (mandatory)
- ECOG performance status 0-1
- No decompensated cirrhosis, active autoimmune disease, or untreated CNS metastases
- Exclude clear tumor infiltration into thoracic great vessels or cavitation of pulmonary lesions
Laboratory monitoring baseline:
- Liver function tests (AST, ALT, bilirubin)
- Renal function (creatinine)
- Complete blood count
- Alpha-fetoprotein (AFP) levels
Ongoing Monitoring
Tumor assessments 1:
- Every 6 weeks for the first 48 weeks
- Every 9 weeks thereafter
- Use RECIST v1.1 criteria
Safety monitoring for immune-mediated adverse events 1:
- Pneumonitis, colitis, hepatitis, endocrinopathies
- Nephritis, dermatologic conditions
- Myocarditis/pericarditis, neurological toxicities
Bevacizumab-specific monitoring 4, 5:
- Hypertension (most common grade 3-4 AE: 13% of patients)
- Proteinuria (grade 3-4: 7% of patients)
- Bleeding complications
- Wound healing complications
Dosage Modifications
No dose reductions are permitted for atezolizumab 1. Management involves withholding or permanent discontinuation:
Withhold treatment for 1:
- Grade 2 pneumonitis, colitis (grades 2-3), nephritis (grades 2-3)
- AST/ALT 3-10× ULN or bilirubin 1.5-3× ULN
- Grade 3 endocrinopathies (until clinically stable)
Permanently discontinue for 1:
- Grade 3-4 pneumonitis
- Grade 4 colitis
- AST/ALT >10× ULN or bilirubin >3× ULN
- Grade 4 nephritis
- Confirmed Stevens-Johnson syndrome, TEN, or DRESS
- Any grade myocarditis/pericarditis
- Grade 3-4 neurological toxicities
- Grade 3-4 infusion reactions
Resume therapy only if 1:
- Complete or partial resolution to Grade 0-1 after corticosteroid taper
- Ability to reduce prednisone to ≤10 mg/day (or equivalent) within 12 weeks
Critical Dosing Considerations
Early bevacizumab modifications significantly impact outcomes 5: Real-world data demonstrate that receiving <45 mg/kg cumulative bevacizumab dose in the first 3 months (equivalent to <10.5 mg/kg per 3-week cycle) is an independent negative prognostic factor with 4.2-fold increased risk of death. Patients with early bevacizumab dose/time modifications had inferior response rates (14% vs 36%) and worse survival (12-month survival 53.3% vs 77.4%). Optimize management of bevacizumab-related adverse events aggressively to maintain full dosing, particularly in the first 3 months 5.
Common Pitfalls to Avoid
- Failing to screen for varices: This is the most critical pre-treatment assessment given bevacizumab's bleeding risk 2
- Treating Child-Pugh B/C patients: Guidelines recommend a "cautious approach" for Child-Pugh B and these patients were excluded from pivotal trials 3
- Reversing infusion order: Always give atezolizumab before bevacizumab 1
- Premature bevacizumab discontinuation: Early dose modifications dramatically worsen outcomes 5
- Delaying corticosteroids for immune-mediated AEs: Prompt management prevents permanent discontinuation 1